Delivery Order SPE2DB24D2011-SPE2DB25FBRUA
- Not listed
- The Defense Logistics Agency awarded a $3,276.48 delivery order to AmerisourceBergen Drug Corp for Ondansetron HCL 8 mg tablets (30-count units) on July 28, 2025, with completion targeted for July 29, 2025. This non-set-aside, competitively awarded contract employs firm fixed pricing and represents a delivery order under AmerisourceBergen's larger pharmaceutical supply agreement. The pharmaceutical will be sourced from the vendor's Conshohocken, Pennsylvania facility, where AmerisourceBergen...
- The Defense Logistics Agency awarded a $17,662.48 delivery order to AmerisourceBergen Drug Corp for Ondansetron ODT 8 mg tablets (30-count package) on August 19, 2025, with an ultimate completion date of August 20, 2025. This competitive, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which carries a potential value of $999,999,999.00 and extends through December 2026. The...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,403.28 to AmerisourceBergen Drug Corp for the supply of Ondansetron HCL 8 mg tablets (30-count) on September 11, 2025, with an ultimate completion date of September 12, 2025. This firm fixed-price, non-set-aside contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $27,766.85 to AmerisourceBergen Drug Corp for Ondansetron ODT 8 mg tablets (30-count supply) on August 12, 2025, with an ultimate completion date of August 13, 2025. This is a firm fixed-price delivery order with no set-aside designation, meaning it was competitively awarded. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract issued under...
- The Defense Logistics Agency awarded a delivery order valued at $5,618.36 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 8 mg tablets in quantities of 30 units. This is a firm fixed price, non-set-aside contract with an ultimate completion date of September 2, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal medical procurement needs, particularly for military and veteran healthcare systems. The delivery...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the provision of Ondansetron HCL 8 mg tablets in 30-count packages. The contract has a potential value of $29,504.32 and a completion date of February 5, 2024. Amerisourcebergen Drug Corp, a for-profit organization, serves as the prime contractor supplying pharmaceutical products and medical supplies to DLA Troop Support...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,812.82 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 8 mg tablets (30-count packages). This competitively awarded, firm fixed-price contract represents a non-set-aside procurement and carries an ultimate completion date of July 22, 2025. The order will be fulfilled from AmerisourceBergen's operations in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters. This delivery order...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,884.12 on July 24, 2025, for the supply of Ondansetron HCl 8 mg tablets (30-count packaging). This is a firm fixed-price, non-set-aside contract with performance completion scheduled for July 25, 2025, and fulfillment based in Conshohocken, Pennsylvania. The award represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated...
- The Defense Logistics Agency awarded a delivery order valued at $26,821.05 to AmerisourceBergen Drug Corp for the supply of Ondansetron HCL 8 mg tablets (30-count packaging), with an ultimate completion date of July 31, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and will be performed at the awardee's corporate headquarters in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions...
- The Defense Logistics Agency awarded a delivery order valued at $5,956.09 to AmerisourceBergen Drug Corp for the supply of Ondansetron HCL 8 mg tablets in quantities of 30 units. This competitive award, issued on September 8, 2025, with an ultimate completion date of September 9, 2025, represents a firm fixed-price delivery order with no set-aside designation. The pharmaceutical product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains...
- SPE2DB24D2011Indefinite Delivery Contract
- SPE2DB24D2011-SPE2DB25FBRUADelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for Ondansetron HCL 8 mg tablets (100-count unit dose packaging) valued at $7,203.47 under a firm fixed-price contract type. The award was made on September 8, 2025, with an ultimate completion date of September 9, 2025, and does not utilize a set-aside designation. Performance will occur at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. This delivery order represents a child contract issued under AmerisourceBergen's larger indefinite delivery contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical vendor, supplies a comprehensive range of medications and medical commodities to support military healthcare programs and federal government customers including the Defense Health Agency and U.S. Coast Guard. The ondansetron procurement represents routine pharmaceutical replenishment under the broader prime vendor arrangement, which enables AmerisourceBergen to fulfill medical supply needs across multiple therapeutic domains on a global basis. The company's federal contract portfolio demonstrates consistent capability to meet DLA procurement requirements through competitive award processes, with delivery orders ranging substantially in value across numerous pharmaceutical product categories.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.2k | 9/8/25 |